[ORGANIZATION]
HC Wainwright
Featured in 27 tracked stories · first seen
Situations
Ocugen clinical trial results and market performance
2 clusters · 6 sources · last updated
Latest: Ocugen earnings estimates raised as Oculis board member resigns
Ocugen experienced significant market volatility following an interim analysis of its OCU410ST gene therapy study for Stargardt disease. Data from the first 26 participants indicated a “negative treatment effect,” causin
Rezolute clinical and financial updates
2 clusters · 4 sources · last updated
Latest: Rezolute reports fiscal 2026 results and clinical updates
Rezolute, Inc. has released its fiscal 2026 financial results and provided updates on its clinical developments regarding the treatment of refractory hypoglycemia caused by hyperinsulinism. The company is currently cond
Also covered in
-
Amprius Technologies receives up to $75 million U.S. grant for drone battery production
[BUSINESS] · 4 sources ·
-
Bioceres Crop Solutions reports 2026 revenue decline amid restructuring
[BUSINESS] · 4 sources ·
-
Calumet shares rise on EPA exemptions and improved earnings estimates
[BUSINESS] · 2 sources ·
-
Disc Medicine faces stock downgrade and FDA regulatory requirements
[BUSINESS] · 2 sources ·
-
Invivyd earnings estimates raised by HC Wainwright
[BUSINESS] · 2 sources ·
-
RenovoRx expands RenovoCath use and targets 2027 pancreatic cancer readout
[BUSINESS] · 3 sources ·
-
Cogent Biosciences receives moderate buy rating from analysts
[BUSINESS] · 2 sources ·
-
Septerna shares hit 52-week high following earnings beat
[BUSINESS] · 2 sources ·
-
HC Wainwright issues updated earnings estimates for Dianthus and Delcath
[BUSINESS] · 2 sources ·
-
Protagonist Therapeutics and PPL report earnings updates
[BUSINESS] · 2 sources ·